Literature DB >> 6685149

Myocardial catecholamines in hypertrophic and dilated (congestive) cardiomyopathy: a biopsy study.

C Kawai, Y Yui, T Hoshino, S Sasayama, A Matsumori.   

Abstract

A high performance liquid chromatographic method was used to determine myocardial norepinephrine and epinephrine concentrations in 66 biopsy specimens obtained from the right or left ventricle during routine diagnostic cardiac catheterization of 45 patients with dilated (congestive) or hypertrophic cardiomyopathy, or with heart disease other than cardiomyopathy, such as acute perimyocarditis, postmyocarditis and constrictive pericarditis. The validity of catecholamine determination in a 2 to 6 mg biopsy specimen to assess overall ventricular myocardial catecholamines was demonstrated. Norepinephrine concentrations in the myocardium were inversely correlated with the grade of hypertrophy in patients with congestive cardiomyopathy or heart disease other than cardiomyopathy, but not in patients with hypertrophic cardiomyopathy. The fact that the myocardial norepinephrine concentration was always lower in the left than in the right ventricle of the same patient may be explained by the simple dilution of sympathetic nerve endings in the left ventricle. There were some cases of hypertrophic cardiomyopathy in which the concentration of myocardial norepinephrine was exceptionally high, although its mean value was not significantly higher than that in patients with other types of heart disease who served as a control group without cardiomyopathy. Some patients with dilated cardiomyopathy had lower levels of myocardial norepinephrine than would be expected for the degree of interstitial fibrosis and the severity of heart failure. The mean plasma norepinephrine and epinephrine levels were significantly elevated in patients with dilated cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6685149     DOI: 10.1016/s0735-1097(83)80229-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  11 in total

1.  Prognostic significance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study.

Authors:  H Ogita; T Shimonagata; M Fukunami; K Kumagai; T Yamada; Y Asano; A Hirata; M Asai; H Kusuoka; M Hori; N Hoki
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

2.  Myocardial beta adrenoceptors and left ventricular function in hypertrophic cardiomyopathy.

Authors:  L Choudhury; S Guzzetti; D C Lefroy; P Nihoyannopoulos; W J McKenna; C M Oakley; P G Camici
Journal:  Heart       Date:  1996-01       Impact factor: 5.994

Review 3.  The many faces of hypertrophic cardiomyopathy: from developmental biology to clinical practice.

Authors:  Iacopo Olivotto; Francesca Girolami; Stefano Nistri; Alessandra Rossi; Luigi Rega; Francesca Garbini; Camilla Grifoni; Franco Cecchi; Magdi H Yacoub
Journal:  J Cardiovasc Transl Res       Date:  2009-10-27       Impact factor: 4.132

4.  Impairments of myocardial sympathetic activity may reflect the progression of myocardial damage or dysfunction in hypertrophic cardiomyopathy.

Authors:  Shinro Matsuo; Yasuyuki Nakamura; Takayoshi Tsutamoto; Masahiko Kinoshita
Journal:  J Nucl Cardiol       Date:  2002 Jul-Aug       Impact factor: 5.952

5.  Long-term course and cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy.

Authors:  M Shimizu; N Sugihara; Y Kita; K Shimizu; Y Horita; K Nakajima; J Taki; R Takeda
Journal:  Br Heart J       Date:  1992-02

6.  Prognostic value of iodine-123 metaiodobenzylguanidine imaging in patients with heart failure.

Authors:  Shinro Matsuo; Yasuyuki Nakamura; Tetsuya Matsumoto; Ichiro Nakae; Kiyoshi Murata; Minoru Horie
Journal:  Exp Clin Cardiol       Date:  2003

7.  Shortening baroreflex delay in hypertrophic cardiomyopathy patients -- an unknown effect of β-blockers.

Authors:  Agnieszka Katarzynska-Szymanska; Romuald Ochotny; Zofia Oko-Sarnowska; Hanna Wachowiak-Baszynska; Tomasz Krauze; Jaroslaw Piskorski; Adrian Gwizdala; Przemyslaw Mitkowski; Przemyslaw Guzik
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

8.  The role of impaired sympathetic nerve function in enhancing coronary vasoconstriction in patients with hypertrophic cardiomyopathy.

Authors:  Shinro Matsuo; Tetsuya Matsumoto; Ichiro Nakae; Minoru Horie
Journal:  Exp Clin Cardiol       Date:  2007

9.  Clinical and echographic features of in utero cardiac dysfunction in the recipient twin in twin-twin transfusion syndrome.

Authors:  N Zosmer; R Bajoria; E Weiner; M Rigby; J Vaughan; N M Fisk
Journal:  Br Heart J       Date:  1994-07

Review 10.  Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone).

Authors:  S A Mortensen
Journal:  Clin Investig       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.